20 episodes

Physician's Weekly offers in-depth interviews with the most highly respected experts in the medical community, weighing in on landmark research, trending topics, and offering insight on issues affecting everyday medical practice. In collaboration with Medicom Medical Publishers, Physician's Weekly Podcast continues to maintain the company's nearly 40 year reputation as a trusted resource for healthcare professionals.

Physician's Weekly Podcast Physician's Weekly

    • Health & Fitness
    • 5.0 • 2 Ratings

Physician's Weekly offers in-depth interviews with the most highly respected experts in the medical community, weighing in on landmark research, trending topics, and offering insight on issues affecting everyday medical practice. In collaboration with Medicom Medical Publishers, Physician's Weekly Podcast continues to maintain the company's nearly 40 year reputation as a trusted resource for healthcare professionals.

    An inDEPTH Look at Chronic Myeloid Leukemia

    An inDEPTH Look at Chronic Myeloid Leukemia

    To acknowledge the Philadelphia Chromosome translocation t(9;22) in chronic myeloid leukemia (CML), every September 22 (9/22) is World CML Day. Today’s podcast episode looks at this topic through different lenses. First, two members of the Lancet Haematology’s committee on adverse events—Jan Geissler, co-founder of the CML Advocates Network, and Gita Thanarajasingam, MD, the committee chair and a hematologist at the Mayo Clinic—discuss how side effects are reported and analyzed and how the committee intends to change that. Geissler also talks about how his experience as a patient with CML led him to become and expert advocate.
     
    Additional reading:
    Geissler J, Huber S. Improving outcomes through patient-generated evidence-the next step in patient advocacy. Lancet Haematol. 2022 Jun;9(6):e399-e400. 
    Thanarajasingam G, et al. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2022 May;9(5):e374-e384
    Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017 Jul 11;318(2):197-198. 

    • 26 min
    An inDEPTH Look at Lymphoma

    An inDEPTH Look at Lymphoma

    September 15 is World Lymphoma Awareness Day, with the theme We Can’t Wait. To honor the leaps and bounds that research into this rare cancer has made, today’s podcast views the current state of lymphoma through different lenses. First, Dr. Constantine Tam, Head of Lymphoma Service at Alfred Hospital and Professor of Hematology at Monash University in Melbourne, Australia talks about the SEQUOIA trial on the efficacy of BTK inhibitor zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukemia and small lymphocytic lymphoma, recently published in Lancet Oncology. 
    Also, Lorna Warwick, CEO of the Lymphoma Coalition, based in Canada as a federation of more than 80 lymphoma patient organizations worldwide that runs the World Lymphoma Awareness Day project, discusses the more than 80 subtypes of non-Hodgkin’s lymphoma. She has some great insights into the unmet needs of patients with lymphoma and how to budge the needle on care.
    Enjoy listening!

    • 24 min
    inDEPTH: What OTC Hearing Aids & Rural Alaska Have in Common

    inDEPTH: What OTC Hearing Aids & Rural Alaska Have in Common

    Today’s episode features two interviews, taking different lenses on news in hearing loss. We first talk with Frank Lin, MD, PhD, at the Johns Hopkins School of Medicine about the various obstacles to hearing health, including new advice on the just FDA-approved OTC hearing aids. He has been part of the FDA rule from the start and tells us a little about how this came to be, as well as some of the benefits. We then speak with Susan D. Emmett, MD, MPH, from the University of Arkansas. She recently led a randomized controlled trial in 15 communities in rural Alaska, looking at whether telemedicine specialty referral can improve time to follow-up for school hearing screening compared with standard primary care referral. Enjoy listening!
     
    Additional reading
     
    Lin FR, Reed NS. Over-the-counter hearing aids: How we got here and necessary next steps. J Am Geriatr Soc. 2022 Jul;70(7):1954-1956. 
     
    Emmett SD, et al. Mobile health school screening and telemedicine referral to improve access to specialty care in rural Alaska: a cluster- randomised controlled trial. Lancet Glob Health. 2022 Jul;10(7):e1023-e1033
     

    • 22 min
    What You Need to Know About Monkeypox & the “Loss of Chance” Malpractice Doctrine

    What You Need to Know About Monkeypox & the “Loss of Chance” Malpractice Doctrine

    Welcome to this episode of Physician’s Weekly podcast. I am your host, Dr Rachel Giles, from Medicom Medical Publishers, in collaboration with Physician’s Weekly. 
    Today’s episode features two interviews. First, we talk about a very timely topic—monkeypox—with public health specialist Dr. Louise Sigfrid from Oxford University. An ongoing outbreak of monkeypox, a viral disease, was confirmed in May 2022. The initial cluster of cases was found in the United Kingdom, where the first case was detected on May 6, 2022 in an individual with travel links to Nigeria. The President Biden administration this month declared the outbreak of monkeypox a public health emergency. Who is at risk? What are the clinical guideline recommendations? Dr. Sigfrid has been involved in the public health response since the beginning of the current outbreak and recently published a paper examining the clinical guidelines for prevention and treatment of monkeypox. 
    Our second interview is with regular contributor and registered radiologist and medical malpractice attorney, Dr. MedLaw. She tells us all about what “loss of chance” means in a medical malpractice claim. Under the loss of chance doctrine, a doctor can be held liable for causing the patient's loss of a chance to be cured if the doctor negligently fails to diagnose a curable disease and the patient is harmed by the disease. 
    Enjoy listening!
     
    Additional reading
     
    Webb E, et al. Availability, scope and quality of monkeypox clinical management guidelines globally: a systematic review. BMJ Glob Health. 2022 Aug;7(8):e009838. doi: 10.1136/bmjgh-2022-009838. PMID: 35973747.  

    • 25 min
    inDEPTH: HIV & Prostate Cancer Prevention

    inDEPTH: HIV & Prostate Cancer Prevention

    Welcome to this episode of Physician’s Weekly podcast. I am your host, Dr. Rachel Giles, from Medicom Medical Publishers, in collaboration with Physician’s Weekly. 
    Today’s episode features two interviews, with an inDEPTH look at prevention. First, we discuss primary prevention of HIV-AIDS from a community global approach, with Rachel Baggaley, MBBS, MSc, the team lead for testing, prevention, and populations in the Global HIV, Hepatitis and STI Programs at the WHO, who has recently published papers in the Lancet HIV and BMJ.  Our second interview is with Alan Pollack, MD, PhD, Chair and Professor of Radiation Oncology at the University of Miami’s Sylvester Comprehensive Cancer Center. He talks us through his recently published trial in the Lancet about a new intervention for secondary prevention of prostate cancer after prostatectomy.
    Enjoy listening!
     
    Additional reading
    Schmidt H, et al. Lancet HIV. 2022;9(5):e363-e366.
    Kennedy C, et al. BMJ Open. 2022;12(2):e054121. 

     Pollack A, et al. Lancet. 2022 May 14;399(10338):1886-1901. 

    • 19 min
    Biomarkers for NSCLC: What You Need to Know - Part 1

    Biomarkers for NSCLC: What You Need to Know - Part 1

    The evolution of biomarkers informing therapy decisions began in 2004, when the FDA approved a medicine to treat EGFR mutated non-small cell lung cancer (NSCLC). Since then, researchers have identified more than 20 distinct mutations in driver genes that are specific to lung cancer, nine of which are treatable through FDA-approved therapy drugs: epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1, BRAF V600E, NTRK, MET, RET, and histological expression of programmed death ligand 1 (PD-L1).
    Confirming a patient's biomarker status can open the door to precision medicine. 
    The molecular characterization of lung cancer has considerably changed the classification and treatment of these tumors, becoming an essential component of pathologic diagnosis and oncologic therapy decisions. The success of targeted anticancer therapies and new immunotherapy approaches has created a new paradigm of personalized therapy and has also led to accelerated development of new drugs for lung cancer treatment. Additional research is needed to identify and help treat the approximately one-third of lung cancer patients for whom biomarkers have yet to be identified.
    This podcast focuses on clinically relevant cancer biomarkers as targets for therapy, as well as potential new targets for drug development. We speak in our first episode with Dr. David M. Waterhouse, who just moved to the Dana Farber Cancer Institute at Harvard Medical School, and until last month was the former Director of Clinical Research at Oncology-Hematology Care, in Cincinnati. We also talk about how these biomarkers are used in academic versus community hospitals. In our second episode, we will talk with Dr. Sinchita Roy Chowdhuri, a molecular pathologist from University of Texas MD Anderson Cancer Center in Houston, about what you didn’t know about actionable biomarkers for NSCLC.

    • 16 min

Customer Reviews

5.0 out of 5
2 Ratings

2 Ratings

You Might Also Like